HTA Quarterly | Winter 2020

By Xcenda |

In this issue, our editors examine ICER's growing influence payer decisions making, subscription-based antibiotic programs, and the path into the German healthcare market for advanced therapy medicinal products.

HTA by the Numbers

50%
A recent “Gallup poll” finds only 50% of respondents are willing to be vaccinated for COVID-19 if an FDA-approved vaccine to prevent it were available at no cost. This is lowest reported willingness to be vaccinated since July, when a high of 66% reported a willingness to be vaccinated.

“The rapid development of COVID vaccines is an administration success; but they'll undermine progress if they thwart the established regulatory process for assuring safety and effectiveness. They should not shortcut these final critical steps”

— Former FDA Commissioner Scott Gottlieb, MD said in a Op-ed for the Wall Street Journal. This comes after months of discussion of COVID-19 vaccine development coverage in the media, and as the US FDA is expected to complete the first review of a COVID-19 vaccine candidate from Pfizer in November.